Smoking Cessation Therapies on the Rise

Each year an estimated three million people die as a result of cigarette smoking complications. However, smoking cessation is on the rise, due to the recent surge in public awareness of the dangers of smoking, legislation banning smoking in many public areas, and the development of pharmacotherapies for the treatment of nicotine addiction.

Smoking Cessation, a new report from Decision Resources, Inc., provides a complete analysis of epidemiology, medical practice, unmet needs, and current and emerging treatments for nicotine addiction.

The current smoking cessation market, valued at $450 million, is dominated by nicotine replacement in multiple delivery forms which include transdermal patch, gum, nasal spray, and the inhaler.

New therapies of nicotine replacement include Glaxo Wellcome's recently approved Zyban and Elan/Sano's late-stage nicotine/mecamylamine patch.

Future pharmacological treatment for smoking cessation will be characterized by the increased use of combination therapies, Zyban, long-term use of nicotine replacement drugs, and the introduction of novel agents.

Smoking Cessation is part of Mosaic, a series of studies on timely topics, focusing on medical indications that are distinguished by major unmet need or significant changes in medical practice.

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., Decision Resources has provided strategic information services for more than 25 years, assessing global industry trends in the international health care and pharmaceutical industries.